New Haven, CT2 Active Studies

Borderline Personality Disorder Clinical Trials in New Haven, CT

Find 2 actively recruiting borderline personality disorder clinical trials in New Haven, CT. Connect with local research sites and explore new treatment options.

2
Active Trials
1
Sponsors
160
Enrolling

Recruiting Borderline Personality Disorder Studies in New Haven

About Borderline Personality Disorder Clinical Trials in New Haven

Borderline personality disorder (BPD) is characterized by instability in moods, behavior, self-image, and interpersonal relationships. It affects about 1.4% of adults. Dialectical behavior therapy (DBT) is the primary treatment, often combined with medications for specific symptoms.

There are currently 2 borderline personality disorder clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 160 participants. Research is being sponsored by Yale University. Clinical trial participation is free and participants receive study-related medical care at no cost.

Borderline Personality Disorder Clinical Trials in New Haven — FAQ

Are there borderline personality disorder clinical trials in New Haven?

Yes, there are 2 borderline personality disorder clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What borderline personality disorder treatments are being tested?

The 2 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for borderline personality disorder.

Data updated October 16, 2026 from ClinicalTrials.gov